Peer-reviewed veterinary case report
Safety of combined doxorubicin and toceranib in dogs with tumors
By Pellin, M. A. et al.·Published in Veterinary and Comparative Oncology·2016·Department of Medical Sciences, School of Veterinary Medicine University of Wisconsin‐Madison Madison WI USA, United States·View original on Crossref →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Safety evaluation of combination doxorubicin and toceranib phosphate (Palladia®) in tumour bearing dogs: a phase I dose‐finding study
- Species:
- dog
Plain-English summary
A group of dogs with tumors received a combination of two cancer treatments: doxorubicin (a chemotherapy drug) and toceranib (a targeted therapy). The goal was to find the safest dose that still worked effectively. While some dogs experienced low white blood cell counts (neutropenia), most tolerated the treatment well without severe side effects. Many showed positive responses to the therapy, suggesting it could help manage their cancer. Further studies are needed to confirm how well this combination works over the long term.
People also search for: dog cancer treatment options · doxorubicin side effects in dogs · toceranib for dog tumors
Abstract
AbstractCombination chemotherapy holds promise for improving outcomes in malignancy when compared with single‐agent approaches. Care must be taken to avoid overlapping toxicity and to utilize agents with differing mechanisms of action. A phase I dose‐finding trial was performed to determine the maximally tolerated dose (MTD) of a concurrent toceranib and doxorubicin (DOX) combination protocol where toceranib dose was maintained at or near 2.75 mg kg−1by mouth every other day (PO EOD) while escalatingDOXdosage. The dose‐limiting toxicity was found to be neutropenia and theMTDof the combination was determined to be 25 mg m−2ofDOXq 21 days given concurrently with toceranib 2.75 mg kg−1PO EOD. This combination was well tolerated with no excessive gastrointestinal toxicity nor novel adverse events (AEs) noted. Anti‐tumour activity was observed in the majority of cases. This combination warrants further investigation in the context of phaseII/IIIclinical trials to characterize efficacy and long‐term AE profiles.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on Crossref: https://doi.org/10.1111/vco.12232